Tehila Ben Moshe
CEO & Co-Founder
Former CEO of cCAM Biotherapeutics, an immunoncology drug discovery company which was acquired by MSD. Prior to that Tehila was member of the R&D broad management team of Protalix BioTherapeutics (AMEX: PLX), where she managed the preclinical development of recombinant biotherapies and advanced them to regulatory filing and clinical trials. Tehila holds a PhD in Biochemistry from the Weizmann Institute of Science focusing on molecular signaling pathways in health and disease.